Trillium Therapeutics (TRIL) Receiving Somewhat Positive Press Coverage, Study Shows

Headlines about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) have trended somewhat positive on Tuesday, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trillium Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1845638591017 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research analysts have weighed in on the company. HC Wainwright set a $7.00 price objective on Trillium Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research raised Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th.

Trillium Therapeutics (TRIL) opened at $9.90 on Tuesday. The company has a quick ratio of 7.92, a current ratio of 7.92 and a debt-to-equity ratio of 0.01. Trillium Therapeutics has a 1 year low of $4.15 and a 1 year high of $10.70.

COPYRIGHT VIOLATION NOTICE: “Trillium Therapeutics (TRIL) Receiving Somewhat Positive Press Coverage, Study Shows” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/14/trillium-therapeutics-tril-receiving-somewhat-positive-press-coverage-study-shows.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Insider Buying and Selling by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply